SANCO prenatal test - Warsaw

See also: Harmony Test, Nifty Test, PAPP-A Test.

Book an appointment

22 100 45 20

SANCO test is a new generation non-invasive genetic prenatal test that determines the risk of trisomies of chromosomes 21, 18 and 13 in the fetus (Down syndrome, Edwards and Patau syndrome), sex chromosome aneuploidies and congenital defect syndromes caused by other chromosomal abnormalities. Trisomies of chromosomes 21, 18, and 13 are the most common congenital defect syndromes caused by the presence of extra copies of these chromosomes. On average, 1 in 800 children is born with Down syndrome (trisomy 21), 1 in 6,000 children is born with Edwards syndrome (trisomy 18) and 1 in 10,000 children is born with Patau syndrome (trisomy 13).

To perform the test, only a small blood sample from the expectant mother is needed, whose plasma contains the child's genetic material (so-called cell-free fetal DNA, cffDNA). Test detectability exceeds 99%. The test allows many expectant mothers to avoid invasive tests (including amniocentesis) that they fear so much. The test can be performed between 10 and 24 weeks of pregnancy.

• To perform the test, only a small blood sample from the expectant mother is needed, whose plasma contains the child's genetic material (so-called cell-free fetal DNA, cffDNA).
• The test is based on technology from American company Illumina, Inc. (world leader in sequencing).
• Test quality is confirmed by CE IVD certificate for the entire process and validation conducted at Genomed S.A.
• Test detectability exceeds 99%.
• High sensitivity and accuracy of the test allows reducing the number of women requiring invasive tests by six times.

SANCO Prenatal Test determines:

• risk of fetal trisomies: Down syndrome, Edwards and Patau syndrome
• risk of sex chromosome number disorders
• risk of selected microdeletion syndromes (SANCO PLUS)
• risk of rare trisomies (SANCO PLUS)
• child's sex

New test – new possibilities

We offer two versions of the test – basic – SANCO and extended – SANCO PLUS. The test can be supplemented with determination of RhD antigen presence in the fetus.

SANCO test can also be performed in case of twin pregnancy, after in vitro fertilization and in egg recipient.

Why SANCO test?

Invasive diagnostics, e.g., amniocentesis or chorionic villus sampling (CVS) are accurate, but carry a 0.5-2% risk of miscarriage. Traditional non-invasive screening tests are characterized by low effectiveness and high risk of false positive results. Non-invasive screening prenatal test type NIPT, such as SANCO, with a false positive result rate below 0.1%, allows reducing the number of women requiring invasive tests by six times.

How does SANCO test work?

SANCO Prenatal Test requires taking a small volume of blood (10ml) from the pregnant woman, in which cffDNA is analyzed to determine chromosomal abnormalities. If aneuploidy is present, during the test an imbalance of the fetal genome will be detected, resulting from excess or deficiency of chromosomes. SANCO test effectively solves the problem of measuring small differences in chromosomal DNA concentration through the use of large-scale sequencing technology. During the test, millions of DNA fragments from the mother and fetus are sequenced. Using genomic sequencing technique with accurate assessment of cfDNA molecule length and proprietary bioinformatics analysis algorithms, SANCO is able to analyze data from the entire fetal genome and, by comparing measurement results relative to fetal fraction, detect the presence of genetic abnormalities.

How to perform SANCO test?

To perform SANCO test, maternal blood is taken (similar to routine diagnostic tests, e.g., complete blood count). No preparation is needed for the test, and fasting is not required. The time to issue results for the basic scope of SANCO test is up to 6 working days from the day the sample is delivered to Genomed S.A. laboratory. For additional questions, answers can be obtained by calling a special helpline: +48 797 660 690 or via email: [email protected].

Quality and safety

Genomed S.A. since May 2015, as the only one in Poland, performs non-invasive genetic prenatal tests in its own laboratory. During a 3-year licensing agreement for NIFTY test, it performed over ten thousand tests, gaining experience that no laboratory in Poland has and only a few in Europe; this is confirmed by the EMQN (European Molecular Quality Network) certificate obtained in 2017 in the field of non-invasive genetic prenatal testing.

Until September 5, 2018, Genomed performed NIFTY test. The end of the licensing agreement allowed for a decision to introduce technology enabling significant increase in laboratory throughput and complete process automation and cost optimization. Currently, in the newly established and fully automated laboratory, Genomed performs under its own SANCO Prenatal Test brand based on Illumina's VeriSeq technology.

In case of receiving an "abnormal" result indicating high probability of fetal trisomy, Genomed will cover the cost of invasive prenatal testing (if it is not performed under health insurance), including the cost of sampling: amniocentesis, trophoblast biopsy (CVS), cordocentesis and the cost of genetic tests: karyotype, fluorescence in situ hybridization (FISH) or equivalent test, up to 1200 PLN. Cost reimbursement will occur only based on the original invoice issued to the Patient by the facility performing the procedure or by paying an invoice issued directly to Genomed SA and after delivering a copy/duplicate of the test result. In justified cases, Genomed may provide genetic counseling and perform genetic testing at its own expense from invasively collected material or otherwise support the diagnostic process.

SANCO test price list

Service available at the following locations:

• Warsaw Wola - price list

Have questions? Contact us - 22 100 45 20.